Integra LifeSciences Holdings Corporation (IART) Stock

Integra LifeSciences Holdings Corporation (IART) is a Healthcare stock trading at $17.60 (as of 2026-06-18), with a market capitalization of $1.25B and a trailing P/E of -2.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Valuation — source: SEC EDGAR (first-party)
Price$17.60
Market Cap$1.25B
P/E Ratio-2.5
EV / EBITDA-4.1
Price / Book1.20
Price / Sales0.76
DCF Value (model)$-13.09
DCF Upside vs Price-174.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.64B
Net Margin-31.6%
Return on Equity-47.6%
Debt / Equity0.69
Current Ratio3.38
Revenue Growth (YoY)1.5%
EPS Growth (YoY)7388.9%
FCF Growth (YoY)-224.4%
Financial Health — source: SEC EDGAR
Altman Z-Score0.72 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Stock P/E-2.5
Sector P/E (Healthcare)21.0
Industry P/E (Medical Equipment)31.7
vs Sector-111.8%
vs Industry-107.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($208.27M)
Institutional Holders Tracked10
Congressional Trades (recent)5
Company
SectorHealthcare
IndustryMedical Equipment
CEOMojdeh Poul
Employees4,396
CountryUS
IPO Date1995-08-16

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • SS Innovations International, Inc. (SSII)
  • MiMedx Group, Inc. (MDXG)
  • Butterfly Network, Inc. (BFLY)
  • Pulse Biosciences, Inc. (PLSE)
  • InMode Ltd. (INMD)
  • SI-BONE, Inc. (SIBN)
  • Embecta Corp. (EMBC)
  • CeriBell, Inc. (CBLL)
IART earnings history · IART institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.